Morocco's Laprophan IPO seven times oversubscribed, lead manager says

Detailed summary
RABAT- Moroccan pharmaceutical company Laprophan's initial public offering was seven times oversubscribed, reflecting strong investor demand for the largest listing on the…
* Investors submitted orders worth 15.3 billion dirhams ($1.5 billion) for an offer seeking to raise 2.22 billion dirhams, according to final estimates from Bachir Tazi, executive director at CFG Bank, the IPO's lead manager
* The IPO, Morocco's third this year, combines the sale of a mix of new and existing shares
* Laprophan, which operates four industrial sites in Morocco and Switzerland, reported revenue of 1.82 billion dirhams ($180 million) in 2025, up from 1.638 billion dirhams a year earlier
* The IPO is intended to support expansion plans, including the acquisition of Polymedic, another Moroccan pharmaceutical company that generated revenue of about 405 million dirhams in 2025, subject to regulatory approval
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here
Opening of the article, excerpted from Zawya. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.zawya.com)



